

PE-Labeled Human HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein



Cat. No. MHC-HM438TP

| Description | |
|---|---|
| Source | <p>Recombinant PE-Labeled Human HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, PE-Labeled Human HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer is assembled by biotinylated monomer and PE-labeled streptavidin.</p> <p>It contains Gly25-Thr305(HLA-C*03:04), Ile21-Met119(B2M) and GADGVGKSAL peptide.</p> |
| Accession | QAV56463.1(HLA-C*03:04)&P61769(B2M)&GADGVGKSAL |
| Wavelength | Excitation Wavelength: 488 nm / 561 nm |
| | Emission Wavelength: 575 nm |
| Endotoxin | Less than 1 EU per µg by the LAL method. |
| Formulation and Storage | |
| Formulation | Supplied as 0.22µm filtered solution in PBS, 0.2% BSA (pH 7.4). |
| Storage | Valid for 6 months from date of receipt when stored at -80°C.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Background | |
| <p>Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.</p> | |